RecruitingPhase 2NCT06053580

Repurposing Valsartan May Protect Against Pulmonary Hypertension


Sponsor

University of Washington

Enrollment

60 participants

Start Date

Feb 28, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether valsartan — a blood pressure medication already widely used — can also help protect against pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs become dangerously narrowed and put strain on the heart. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with WHO Group 1 pulmonary arterial hypertension - Your right heart catheter test confirmed elevated lung artery pressure - You are in NYHA functional class II, III, or IV (mild to severe symptoms) - You can walk at least 50 meters on your own **You may NOT be eligible if...** - You have significant kidney or liver disease - You have dangerously low blood pressure or are pregnant - You are already on medications that interact badly with valsartan (e.g., certain potassium-sparing diuretics or ACE inhibitors in some combinations) - You have had a recent hospitalization for worsening heart failure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGValsartan 40 mg

Valsartan 40mg twice daily for 24 weeks.

DRUGPlacebo

Placebo twice daily for 24 weeks.


Locations(1)

University of Washington Medical Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06053580


Related Trials